Posters
High-Resolution Detection of Structural Variants Associated with Leukemia Using EGM
Structural variants such as TP53 deletions and PML::RARA gene fusions are clinically significant in hematologic malignancies, yet remain challenging to detect with traditional sequencing and cytogenetic tools. The Nabsys OhmX™ Platform, powered by electronic genome mapping (EGM), delivers scalable, cost-effective, and high-confidence detection of these variants—enabling breakthroughs in translational cancer research.
In this poster, you’ll learn:
- How EGM overcomes the limitations of short-read sequencing, long-read sequencing, and FISH/CMA
- High-resolution mapping of TP53 deletions (87 kb to 3.8 kb) in leukemic cell lines
- Confirmation of PML::RARA reciprocal translocations using a dense tagging and electronic detection strategy
- Why EGM is a valuable complement to sequencing and cytogenetics in hematopathology
With its ability to detect variants as small as 300 bp and provide clear, orthogonally validated insights, the OhmX™ Platform sets a new benchmark for precision SV detection in leukemia.
Download Now
Please complete the form to download this poster.
Share This
Cancer Research
Gain deeper insights and drive breakthroughs in cancer research with the OhmX™ Platform, powered by electronic genome mapping (EGM) and expertly engineered to unravel the complexities of structural variants (SVs) in cancer genomes.
Orthogonal Validation of NGS and LRS
Gain confidence in your genomic discoveries from NGS and long-read sequencing (LRS) platforms with a low-cost solution to verify, clarify, and identify structural variant (SV) calls.
Rare Disease
Unravel complexities and gain critical insights with the OhmX™ Platform, designed to help you push the boundaries of rare disease research.
Cell and Gene Therapy
EGM provides clarity to genomic integrity where other tools can’t.